Short Summary
The Plaintiffs filed suit alleging that the Defendants are infringing upon their patented pharmaceutical composition, IN 382949, and also copying content from the Plaintiffs' website. The Suit Patent covers a synergistic combination of Lactoferrin and Guanosine Nucleotide for treating anaemia. Based on the prima facie evidence presented, the Court granted an ad-interim injunction restraining the Defendants from marketing or selling the infringing product 'FERROTOK PLUS', while also allowing interim protection for the Plaintiffs' copyright.
Detailed Summary
of the Paris Local Division of the Unified Patent Court concerning a request for extension of time filed by the Bosch defendants. The judge-rapporteur rejected Bosch's request, finding that a non-redacted version of Valeo's 15 June 2026 filing had been deposited in the CMS simultaneously with the redacted version, and that Bosch had failed to exercise due diligence in accessing it. The court ruled that the deadlines under R.29(d) RdP run from 15 June 2026.
Practitioner Note
This case demonstrates the evidentiary and procedural standards applied in patent matters before Delhi High Court. Understanding the court's reasoning in Frimline Private Limited vs K-Smatco Lifesciences Private Limited is valuable context for structuring arguments or assessing risk in similar proceedings.
Related Cases
Chivas Holdings (Ip) LimitedvsMcdowell And Company Limited
The Madras High Court allowed Chivas Holdings' petition seeking the removal and rectification of a conflicting trademark registration, 'Tribute,' in Class 33. The court noted that Respondent No. 2 (United Spirits Limited) had filed an application for cancellation of this specific mark. Consequently, the court directed the Registrar of Trade Marks to rectify the register by removing Trademark Registration No. 636945 from the records.
Walter Bushnell Pvt Ltd.vsGalaxi Drugs Pvt Ltd.
The Delhi High Court disposed of a trademark cancellation petition filed by Walter Bushnell Pvt Ltd. against Galaxi Drugs Pvt Ltd. The dispute centered on the conflicting marks 'DROTIN' and 'DROTAGAN' in Class 5 (pharmaceuticals). Crucially, the parties reached an out-of-court settlement, leading to Respondent No.1 agreeing to surrender its registration for 'DROTAGAN' and acknowledging the Petitioners' rights in 'DROTIN'. The court accepted this agreement, effectively resolving the dispute.
OCV Intellectual Capital LlcvsThe Controller General of Patents, Designs and Trademarks
The appeal challenged the rejection of a patent application for a high-performance glass fiber composition that achieves S-glass properties at a lower manufacturing cost. The Controller rejected it based on lack of novelty, inventive steps, and non-patentable subject matter. The High Court set aside the rejection order, finding that the Controller failed to consider key arguments regarding technical advancement and synergistic effect.
Pharma Cinq, LlcvsThe Controller General of Patents, Designs and Trademarks
Pharma Cinq, Llc filed an appeal challenging an earlier order passed by the Controller of Patents concerning Indian Patent Application no. 202017028792. The court also addressed several interlocutory applications related to filing procedures.
Mr. Anil Gopalji ThackervsMr. Davda Jaydeepkumar Jagdishchandra
The appellant (plaintiff) filed a Trademark Suit against the respondent (defendant) alleging infringement by using the similar trade name 'Kshetrapal Construction'. The appeal challenged the trial court's order rejecting the application for an interim injunction. The High Court dismissed the appeal, finding that the plaintiff failed to establish secondary meaning and had suppressed material facts.
Dealing with a patent challenge?
Whether it's a Section 3(d) rejection, a post-grant opposition, or a FRAND dispute, Arctic's patent litigation team has handled it. Get a strategy call.
Disclaimer: This page contains an automated summary based on publicly available judicial records. The content is generated for informational purposes only and does not constitute legal advice. Always verify details against the original source judgment before relying on this information for any legal purpose. If you believe any information is inaccurate, please contact us.